Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.97 |
| ▸ | CTSL | P07711 | 5/20 | 0.97 |
| ▸ | GHSR | Q92847 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26993704 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL29411985 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL29367405 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL25422114 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL30472916 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL25424145 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL472759 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL30913016 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL21065454 | 0.98 | CTSV (1.00) | CTSVCTSLGHSRKDM4EALDH1A1 | |
| SCHEMBL7835926 | 0.95 | CTSV (0.88) | CTSVCTSLGHSRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108610286-B | 2-aryl-4-quinolone derivative and preparation method and application thereof | 绍兴文理学院 | 2021-12-03 | — | — | CN | claimed |
| CN-108610286-A | A kind of 2- aryl-4-quinolones derivative and its preparation method and application | 绍兴文理学院 | 2018-10-02 | — | — | CN | claimed |
| US-9023867-B2 | Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | claimed |
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-19 | — | — | US | claimed |
| US-8440692-B2 | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-05-14 | — | — | US | claimed |
| EP-2096924-B1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | UNIV CHINA MEDICAL (TW) | 2013-02-13 | — | — | EP | claimed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | claimed |
| EP-2096924-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | China Medical University (TW) | 2009-09-09 | — | — | EP | claimed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | claimed |
| WO-1994002145-A2 | 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| CN-108610286-B | 2-aryl-4-quinolone derivative and preparation method and application thereof | 绍兴文理学院 | 2021-12-03 | — | — | CN | disclosed |
| CN-108610286-B | 2-aryl-4-quinolone derivative and preparation method and application thereof | 绍兴文理学院 | 2021-12-03 | — | — | CN | disclosed |
| CN-108610286-B | 2-aryl-4-quinolone derivative and preparation method and application thereof | 绍兴文理学院 | 2021-12-03 | — | — | CN | disclosed |
| CN-108617661-A | A kind of application of alkaloid compound in agricultural drugs | 中国海洋大学 | 2018-10-09 | — | — | CN | disclosed |
| CN-108623563-A | A kind of application of quinolinones compound in drug | 中国海洋大学 | 2018-10-09 | — | — | CN | disclosed |
| WO-1994002145-A2 | 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, SLC20A1 | CTSV 4446/4885CTSL 4012/4885GHSR 4248/4885 |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | CTSV 4217/4885CTSL 3581/4885GHSR 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.